Search

everythinglearnresearchcommunity

for

Search:↓

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.

Control variability makes it hard to confirm low-dose endocrine effects.

New compounds were made that effectively block a specific enzyme related to androgen conditions.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

ANE syndrome is caused by a mutation in the RBM28 protein that disrupts ribosome assembly.

Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.

Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

The Bethesda system is effective for identifying thyroid cancer but has low sensitivity.

Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.

Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.

The research found how GPCR Class A Rhodopsin receptors are related and suggested possible substances they interact with.

Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.

SSAT is a key enzyme affecting cell growth and metabolism, with potential but risky use in disease treatment.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.

The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.

Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Adding a second method to PROTACs could improve cancer treatment.

Localized ROS production is essential for cell growth and movement in plants and animals.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.